Astra Zeneca {AZN: A2/A): Company Update





Astra Zeneca released a bullish note today in which they anticipate:

• Revenue of $80b annually by 2030 (up from $45b 2023)
• 20 new drugs delivered – many with $5bn Peak Year revenues.
• Growth coming from Oncology, BioPharma and Rare Disease portfolio.

Investor day link: {www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html}